Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $60.8 million.

  • Celldex Therapeutics' Cash from Investing Activities rose 2740.69% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.7 million, marking a year-over-year increase of 13661.25%. This contributed to the annual value of -$290.1 million for FY2024, which is 17427.07% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Cash from Investing Activities is $60.8 million, which was up 2740.69% from $49.8 million recorded in Q2 2025.
  • Celldex Therapeutics' Cash from Investing Activities' 5-year high stood at $60.8 million during Q3 2025, with a 5-year trough of -$315.2 million in Q1 2024.
  • Over the past 5 years, Celldex Therapeutics' median Cash from Investing Activities value was $23.1 million (recorded in 2022), while the average stood at -$19.4 million.
  • In the last 5 years, Celldex Therapeutics' Cash from Investing Activities surged by 40644.51% in 2023 and then crashed by 411400.34% in 2024.
  • Celldex Therapeutics' Cash from Investing Activities (Quarter) stood at -$18.9 million in 2021, then surged by 264.76% to $31.2 million in 2022, then crashed by 648.36% to -$171.2 million in 2023, then skyrocketed by 114.05% to $24.0 million in 2024, then soared by 153.03% to $60.8 million in 2025.
  • Its Cash from Investing Activities stands at $60.8 million for Q3 2025, versus $49.8 million for Q2 2025 and $42.9 million for Q1 2025.